New findings may begin to explain why some people have milder COVID-19 symptoms than others. The study suggests that people with COVID-19 may experience milder symptoms because CD8+ T cells “remember” previous encounters with seasonal coronaviruses. In this case, these cells are better equipped to mobilize quickly against an infection with SARS-CoV-2. In addition, the study showed that the killer T cells taken from the sickest COVID-19 patients exhibit fewer signs of having had previous run-ins with common-cold-causing coronaviruses.

This research is published in Science Immunology in a paper titled, “CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients.”

Discussions about immunity to COVID-19 often center on antibodies. But antibodies are easily fooled, said senior author Mark Davis, PhD, a professor of microbiology and immunology at Stanford University and a Howard Hughes Medical Institute investigator. “Pathogens evolve quickly and ‘learn’ to hide their critical features from our antibodies,” he noted. But T cells recognize pathogens in a different way, and they’re tough to fool.

When a killer T cell is activated, upon recognition of a peptide displayed on a cell’s surface from an invading pathogen (peptide-MHC), it generates memory T cells. These cells persist in the blood and lymph, often for decades, ready to spring into action upon recognition of the same peptide a second time.

To uncover the differences in COVID-19 disease severity, Vamsee Mallajosyula, PhD, postdoctoral fellow in the Davis lab, first confirmed that some portions of SARS-CoV-2’s sequence are effectively identical to analogous portions of one or more of the four widespread common-cold-causing coronavirus strains. Then he assembled a panel of 24 different peptide sequences that were either unique to proteins made by SARS-CoV-2 or are also found on similar proteins made by one or more (or even all) of the seasonal strains.

More specifically, the study reported the development of “an improved multimeric αβ T cell staining reagent platform, with each maxi-ferritin ‘spheromer’ displaying 12 peptide-MHC complexes.” Spheromers, the authors noted, stain specific T cells more efficiently than peptide-MHC tetramers and capture a broader portion of the sequence repertoire for a given peptide-MHC.

The researchers analyzed blood samples taken from healthy donors before the COVID-19 pandemic began, meaning they’d never encountered SARS-CoV-2. That said, many had presumably been exposed to common-cold-causing coronavirus strains. The scientists determined the numbers of T cells targeting each peptide represented in the panel.

They found that unexposed individuals’ killer T cells targeting SARS-CoV-2 peptides that were shared with other coronaviruses were more likely to have proliferated than killer T cells targeting peptides found only on SARS-CoV-2. The T cells targeting those shared peptide sequences had probably previously encountered one or more coronavirus strains—and had proliferated in response, Davis said.

Many of these killer T cells were in “memory” mode, David said. “Memory cells are by far the most active in infectious-disease defense,” he added. “They’re what you want to have in order to fight off a recurring pathogen. They’re what vaccines are meant to generate.”

Killer T cells whose receptors target peptide sequences unique to SARS-CoV-2 must proliferate over several days to get up to speed after exposure to the virus, Davis said. “That lost time can spell the difference between never even noticing you have a disease and dying from it,” he said.

To test this hypothesis, Davis and his colleagues turned to blood samples from COVID-19 patients. They found that COVID-19 patients with milder symptoms had more killer-T memory cells directed at peptides SARS-CoV-2 shared with other coronavirus strains. Sicker patients’ expanded killer T-cell counts were mainly among those T cells typically targeting peptides unique to SARS-CoV-2 and, thus, probably had started from scratch in their response to the virus.

“It may be that patients with severe COVID-19 hadn’t been infected, at least not recently, by gentler coronavirus strains, so they didn’t retain effective memory killer T cells,” Davis said.

Davis noted that cold-causing seasonal coronavirus strains are rampant among children, who rarely develop severe COVID-19 even though they’re just as likely to get infected as adults are. “Sniffles and sneezes typify the daycare setting,” he said, “and coronavirus-caused common colds are a big part of the reason. As many as 80% of kids in the United States get exposed within the first couple of years of life.”

Previous articlePharmacological Activation of p53 Boosts Immune Response against Tumors
Next articleMemory of Centromere Encoded in Epigenome One Generation Deep